thumbnail image
broken image
broken image

seek and you will find

  • Home
  • Technology
  • Products 
    • Products Overview
    • SeekInCare
    • SeekInCure
    • SeekInClarity
    • OncoSeek
    • LeukoPrint
  • Publication 
    • Research
    • Others
  • Newsroom
  • Product & Service Inquiry
  • …  
    • Home
    • Technology
    • Products 
      • Products Overview
      • SeekInCare
      • SeekInCure
      • SeekInClarity
      • OncoSeek
      • LeukoPrint
    • Publication 
      • Research
      • Others
    • Newsroom
    • Product & Service Inquiry
    broken image
    broken image

    seek and you will find

    • Home
    • Technology
    • Products 
      • Products Overview
      • SeekInCare
      • SeekInCure
      • SeekInClarity
      • OncoSeek
      • LeukoPrint
    • Publication 
      • Research
      • Others
    • Newsroom
    • Product & Service Inquiry
    • …  
      • Home
      • Technology
      • Products 
        • Products Overview
        • SeekInCare
        • SeekInCure
        • SeekInClarity
        • OncoSeek
        • LeukoPrint
      • Publication 
        • Research
        • Others
      • Newsroom
      • Product & Service Inquiry
      broken image
      • SeekIn envisions that by leading a new norm for cancer early detection the clinical outcome of mid-/late-stage cancer patients can be reversed and the cancer mortality rate can be reduced by 15%.

        Explore SeekIn's products
      • About Us

        broken image

        SeekIn Inc. is a biotech company founded in 2017, focusing on blood-based pan-cancer early detection utilizing next-generation sequencing and artificial intelligence. Since its creation, SeekIn has been committed to providing cutting-edge and cost-effective solutions for cancer early detection, postoperative recurrence monitoring, and treatment response evaluation. SeekIn has also developed novel molecular tests for leukemia patients, and its cancer early detection technology has been successfully applied to canines. With its proprietary technical advances, SeekIn has launched a number of research and clinical studies in collaboration with top-tier hospitals in Europe and China. SeekIn envisions that, by leading a new norm for cancer early detection, the clinical outcomes of mid-/late-stage cancer patients can be reversed, and the cancer mortality rate can be reduced by 15%.

      • The management team of SeekIn consists of experts with insightful and complementary experiences in R&D, clinical lab management, business operations, corporate finance, and product commercialization.

        See the founder

        In October 2020,Dr. Mao Mao was invited to give a talk on TEDxTheBoud's annual meeting again (TEDxTheBund talk in 2018). As TED's vision is the power of ideas to change the world, his wish is to use early detection to control cancer, the emperor of all maladies.

         

        I hope that with all our efforts today, when we identify a positive case, the person will say to me, "Dr. Mao, no worries. I just have cancer".

        ——— Mao Mao

        Dr. Mao Mao's TEDxTheBund talk in 2020

        In 2024, Dr. Mao Mao was invited to deliver a speech on the AACR Annual Meeting, the world's largest cancer research conference.

         

        Early cancer detection can improve cure rates and five-year survival rates, yet many established cancer screening technologies are not suitable for use in low- and middle-income countries due to their cost, complexity, and reliance on extensive medical infrastructure. OncoSeekTM is designed to address these challenges.

        ——— Mao Mao

        Dr. Mao Mao 's AACR Annual Meeting talk in 2024

      • Our Solution

        multiplex, stepwise, cost-effective blood-based cancer screening

        broken image

         

        A NGS test to capture cancer genetic features in plasma

        broken image

         

        To calculate cancer risk score

        broken image

         

        Non-invasive blood based screening method,10ml blood

      •  

        Newsroom

        From Non-Invasive Early Detection to Treatment Response Monitoring: ...
        May 20, 2025 · Press Releases
        2025 European Debut: SeekIn Presents Cost-Effective Two-Step Multi-Cancer...
        May 15, 2025 · Press Releases
        Longevity Medical Institute™ Integrates OncoSeek® to Launch One of ...
        April 8, 2025 · Media Resources
        BIOS and OncoInv have joined in partnership to bring cancer detection...
        March 21, 2025
        SeekIn's Two-Step Multi-Cancer Early Detection Method May Reduce False...
        January 24, 2025 · Media Resources
        SeekIn Publishes A Cost-Effective Two-Step Approach for Multi-Cancer Early...
        January 22, 2025
        More Posts
      •  

        Partnerships

        broken image
        broken image
        broken image
        broken image
        broken image
        broken image
        broken image
        broken image
        broken image

      Navigation

      Technology   

      SeekInCare

      SeeInCure

      SeekInClarity

      OncoSeek

      Research

      Contact Us

      10320 Camino Santa Fe, Suite G

      San Diego, CA 92121

      United States

      info@seekincancer.com

      © 2024 SeekIn Inc.

      All Rights Reserved.

      Cookie Use
      We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
      Learn More